Helicobacter pylori eradication is superior to ulcer healing with or without maintenance therapy to prevent further ulcer haemorrhage

Alimentary Pharmacology and Therapeutics

Volumn 15, Issue 12, 2001, Pages 1939-1947

  Sharma, V K ^a   Sahai, A V ^b   Corder, F A ^a   Howden, C W ^c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BISMUTH CITRATE; BISMUTH SALICYLATE; CLARITHROMYCIN; HISTAMINE H2 RECEPTOR ANTAGONIST; METRONIDAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; TETRACYCLINE;

ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; ERADICATION THERAPY; GASTROINTESTINAL INFECTION; HELICOBACTER PYLORI; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; META ANALYSIS; PEPTIC ULCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; ULCER HEALING;

ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; BISMUTH; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MEDLINE; METRONIDAZOLE; OMEPRAZOLE; ORGANOMETALLIC COMPOUNDS; PEPTIC ULCER HEMORRHAGE; RANDOMIZED CONTROLLED TRIALS; RANITIDINE; RECURRENCE; RISK FACTORS; SALICYLATES; SENSITIVITY AND SPECIFICITY;

EID: 0035666303     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2001.01134.x     Document Type: Article

References (30)

1. Clinical expression of H. pylori infection
2. The report of the Digestive Health Initiative International Update Conference on Helicobacter pylori
3. Analysis of 3.294 cases of bleeding in military medical facilities
4. What is the role of Helicobacter pylori in complicated ulcer disease?
5. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in peptic ulcer disease
6. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: A review
7. Highly significant change of the clinical course of relapsing and complicated peptic ulcer disease after cure of Helicobacter pylori infection
8. Cure of duodenal ulcer disease associated with eradication of Helicobacter pylori
9. Cost-effectiveness of Helicobacter pylori eradication for the long-term management of duodenal ulcer in Canada
10. Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials
11. Meta-analysis, decision analysis and cost-effectiveness analysis. Methods for quantitative synthesis in medicine
12. The number needed to treat: A clinically useful measure of treatment effect
13. Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease
14. Eradication of Helicobacter pylori reduces the possibility of rebleeding in peptic ulcer disease
15. Helicobacter pylori eradication reduces the rate of rebleeding in ulcer hemorrhage
16. Treatment of Helicobacter pylori in patients with duodenal hemorrhage - A long-term randomized, controlled study
17. Eradication of Helicobacter pylori in patients with duodenal ulcer hemorrhage - 5-Year follow up
18. Eradication of Helicobacter pylori reduces the rate of rebleeding in complicated ulcer disease
19. Cure with omeprazole plus amoxicillin versus long-term ranitidine therapy in Helicobacter pylori-associated peptic ulcer disease
20. One-week antibiotics versus maintenance acid suppression therapy for Helicobacter pylori-associated peptic ulcer bleeding
21. Antimicrobial therapy for Helicobacter pylori infection versus long-term maintenance antisecretion treatment in the prevention of recurrent hemorrhage from peptic ulcer: Prospective nonrandomized trial on 125 patients
22. Eradication of Helicobacter pylori or H2 blocker maintenance therapy after peptic ulcer bleeding. A prospective randomized trial
23. Rolling review: Upper gastrointestinal bleeding
24. Maintenance ranitidine treatment after haemorrhage from a duodenal ulcer: A 3-year study
25. A controlled study of ranitidine for the prevention of recurrent hemorrhage from duodenal ulcer
26. Twenty-four-hour intragastric pH: Tolerance within 5 days of continuous ranitidine administration
27. For what conditions is there evidence-based justification for treatment of Helicobacter pylori infection?
28. Screening for Helicobacter pylori and nonsteroidal anti-inflammatory drug use in Medicare patients hospitalized with peptic ulcer disease
29. Long-term Helicobacter pylori recurrence after successful eradication with triple therapy
30. Guidelines for the management of Helicobacter pylori infection